RxDoctor Payments Data

Andres Serrano, MD

Nephrology · Chicago, ILNPI 1336354562

Payments from drug & device makers

$11,798in general payments, 2019–2025

Across 91 payments — averaging $129.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$10K
  • Fresenius USA Marketing, Inc.$597
  • Amgen$240
  • AstraZeneca$203
  • Otsuka America Pharmaceutical, Inc.$139
  • Travere Therapeutics, Inc.$130
  • plus $580 from 11 others

What the payments were for

  • Food & beverage$1,89597%
  • Education$533%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,798 in reported general payments places this provider in the 85th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$99,001
Medicare patients
184
Services billed
706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol67$56,139
JardianceEmpagliflozin30$19,144
LokelmaSodium Zirconium Cyclosilicate25$18,127
Sevelamer Carbonate40$13,385
TradjentaLinagliptin12$5,468
Nifedipine ErNifedipine31$872
Losartan Potassium47$427
Calcitriol41$415
Furosemide54$376
Lisinopril25$223
Pantoprazole Sodium11$170
Carvedilol23$153
Atorvastatin Calcium17$151
Gabapentin19$149
Amlodipine Besylate29$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$203$74,26692 claims
Boehringer IngelheimJardiance, Tradjenta$66$24,61242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 524 nephrology providers in Illinois.

Other nephrology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →